

continuing education quiz: patient counseling
**New Drugs of 2003 for Treatment of Cancer:
 Iressa and Velcade**

1. All of the following are classified as non-small cell lung cancer EXCEPT:
 - a. adenocarcinoma.
 - b. large cell.
 - c. oat cell.
 - d. squamous cell.
2. The type of cancer cell that is spindle-shaped with multiple sides is referred to as:
 - a. intermediate cell.
 - b. large cell.
 - c. oat cell.
 - d. squamous cell.
3. The most common form of lung cancer worldwide is:
 - a. adenocarcinoma.
 - b. intermediate cell.
 - c. oat cell.
 - d. squamous cell.
4. At present, smoking is attributed to causing which of the following percentages of lung cancer deaths?
 - a. nearly 30 percent
 - b. nearly 50 percent
 - c. nearly 70 percent
 - d. nearly 90 percent
5. After smoking, the second leading cause of lung cancer in the U.S. is exposure to:
 - a. hydrocarbons.
 - b. radon.
 - c. asbestos.
 - d. chromium.
6. Multiple myeloma is most likely to cause:
 - a. hypercalcemia.
 - b. hyperglycemia.
 - c. hyperkalemia.
 - d. hyponatremia.
7. Gefitinib acts by inhibiting phosphorylation of:
 - a. proteasomes.
 - b. cytochrome oxidases.
 - c. tyrosine kinases.
 - d. chromosomes.
8. Patients receiving gefitinib should be told the dose:
 - a. should be taken with food.
 - b. can be taken with or without food.
 - c. must be taken on an empty stomach.
9. Bortezomib acts by inhibiting the activity of:
 - a. proteasomes.
 - b. cytochrome oxidases.
 - c. tyrosine kinases.
 - d. chromosomes.
10. The dosage regimen for bortezomib is:
 - a. twice daily for two weeks.
 - b. twice daily for two months.
 - c. twice weekly for two weeks.
 - d. twice weekly for two months.



Return for Educational Credit
**New Drugs of 2003 for Treatment of
 Cancer: Iressa and Velcade**

Jan 2004 ACPE NO. 129-047-03-011-H01



The Ohio Pharmacists Foundation Inc and NDSU College of Pharmacy are approved by ACPE as providers of continuing pharmaceutical education. To receive 1 ½ hours (0.15 CEUs) of continuing education credit, complete the following and mail with \$5.00 to:

Continuing Education Secretary
 College of Pharmacy
 North Dakota State University
 Sudro Hall, Room 123
 Fargo, ND 58105

Name _____

Social Security Number (SSN) _____

Address _____

City _____ State _____

Zip _____

Your SSN will be used to maintain a permanent record of the courses you have taken. Your SSN will be kept confidential and will be used ONLY to identify you at NDSU.

COURSE EVALUATION	ANSWER SHEET
Evaluation Must Be Completed To Obtain Credit	
How much time did this lesson require ?	1. a b c d
_____	2. a b c d
_____	3. a b c d
_____	4. a b c d
_____	5. a b c d
_____	6. a b c d
Today's Date	7. a b c d
_____	8. a b c d
_____	9. a b c d
_____	10. a b c d

EXPIRATION DATE:
11-15-06

Learning objectives on first page were addressed.

	1 Disagree - 5 Agree
Objective 1	1 2 3 4 5
Objective 2	1 2 3 4 5
Objective 3	1 2 3 4 5

Material was well organized and clear.	1 2 3 4 5
Content sufficiently covered the topic.	1 2 3 4 5
Material was non-commercial in nature.	1 2 3 4 5